Instrument Inactif

Communiqués CM Life Sciences III Inc. Nasdaq

Actions

CMLTU

US1258412055

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

CM Life Sciences III : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION - Form 8-K	20/12/21	PU
CM Life Sciences III : Submission of Matters to a Vote of Security Holders - Form 8-K	17/12/21	PU
CM LIFE SCIENCES III INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	17/12/21	AQ
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination	02/12/21	BU
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference	29/11/21	BU
CM LIFE SCIENCES III INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q/A)	23/11/21	AQ
CM LIFE SCIENCES III INC. : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	23/11/21	AQ
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa	22/11/21	BU
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series	16/11/21	BU
CM LIFE SCIENCES III INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	15/11/21	AQ
CM LIFE SCIENCES III INC. : Entry into a Material Definitive Agreement (form 8-K)	29/10/21	AQ
EQRx : and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs	19/10/21	BU
EQRx : Appoints Kathy Giusti to Board of Directors	27/09/21	BU
EQRx : Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021	17/09/21	BU
EQRx : Appoints Richard Buckley as Chief Corporate Affairs Officer	18/08/21	BU
CM LIFE SCIENCES III : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	16/08/21	AQ
CM LIFE SCIENCES III INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure (form 8-K)	06/08/21	AQ
CM Life Sciences III : EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III	06/08/21	BU
CM LIFE SCIENCES III INC. : Change in Directors or Principal Officers (form 8-K)	03/08/21	AQ
CM LIFE SCIENCES III INC. : Other Events (form 8-K)	02/06/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CM Life Sciences III Inc. Nasdaq

Actions

CMLTU

US1258412055

Communiqués

Filtres